This medicine is imported from Europe. The medicine is made by Novartis under the brand name Rahika and is the exact same product as the brand Tabrecta. Save over 60% on this medicine with insulinhub.
Manufactured by: Novartis Oeflingerstrasse 44 D-79664 Wehr, Germany
Information about Tabrecta (Capmatinib)
Tabrecta is a prescription medication that contains capmatinib, an oral drug used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations. Capmatinib works by targeting and inhibiting MET, a protein that is involved in the growth and spread of cancer cells. MET mutations or amplifications are commonly found in certain types of lung cancer. By blocking this protein, Tabrecta helps slow the progression of cancer and may improve outcomes for patients with this specific genetic alteration.
Product Highlights
- Tabrecta is primarily indicated for the treatment of non-small cell lung cancer that has a specific genetic mutation known as MET exon 14 skipping. This mutation leads to uncontrolled growth of cancer cells, and capmatinib targets this abnormality.
- It is effective for patients with locally advanced or metastatic NSCLC with MET exon 14 mutations, particularly in cases where other treatments have not been effective.
Key Ingredient
Key Benefits
- Capmatinib provides a targeted approach to treating NSCLC with MET exon 14 mutations, offering a more specific and effective alternative to traditional chemotherapy.
- Clinical studies have shown that Tabrecta can lead to significant improvements in progression-free survival and overall response rates in patients with MET-driven NSCLC.
- As an oral tablet, Tabrecta offers convenience for patients compared to intravenous treatments, allowing for easier at-home use.
- Since capmatinib targets MET mutations specifically, it may have a lower risk of affecting healthy, non-cancerous cells, potentially leading to fewer side effects compared to traditional chemotherapy.
Direction of Use
- Tabrecta is taken orally, typically once or twice a day with food. The tablets should be taken whole and should not be broken or chewed.
- The usual recommended dosage is 400 mg (two 150 mg tablets) taken once daily. However, the dosage may vary depending on the patient's specific condition and the healthcare provider’s assessment.
- Regular monitoring is necessary, including blood tests to check for liver function, as liver toxicity can occur with capmatinib.
- If you miss a dose, take it as soon as you remember, unless it's almost time for the next dose. In that case, skip the missed dose.
Safety Concerns
- Capmatinib can cause liver damage, including elevated liver enzymes or liver failure in some cases. Regular monitoring of liver function is required during treatment.
- Rarely, patients may develop interstitial lung disease, a serious condition that affects the lungs. Symptoms may include difficulty breathing, coughing, and a fever. If these symptoms occur, prompt medical attention is required.
- Common side effects of Tabrecta include diarrhea, nausea, and vomiting. Patients may require medication to control these symptoms.
- Some patients may experience fatigue, which can affect daily activities and quality of life.
- Tabrecta may interact with certain medications, particularly those that affect liver enzymes, so it’s important for patients to inform their healthcare provider about all other drugs they are taking.
Avoid Tabrecta (Capmatinib) If
- Tabrecta should be avoided or used with caution in patients with moderate to severe liver impairment, as it may exacerbate liver damage.
- Patients who are allergic to capmatinib or any other components of Tabrecta should not take this medication.
- Capmatinib can cause harm to a fetus and should not be used during pregnancy. It is also not advised during breastfeeding, as it may be passed into breast milk.
- If a patient has a history of interstitial lung disease or pulmonary issues, they should avoid using Tabrecta due to the potential risk of exacerbating lung conditions.
- Patients should inform their healthcare provider about any other medications they are taking, particularly those that influence liver enzymes, as Tabrecta may interact with these drugs.
